Research ArticleCancer
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
- Otto Kauko1,2,3,*,
- Caitlin M. O’Connor4,†,
- Evgeny Kulesskiy5,†,
- Jaya Sangodkar6,
- Anna Aakula1,
- Sudeh Izadmehr6,
- Laxman Yetukuri1,
- Bhagwan Yadav5,
- Artur Padzik1,
- Teemu Daniel Laajala5,7,
- Pekka Haapaniemi1,
- Majid Momeny1,
- Taru Varila1,
- Michael Ohlmeyer6,
- Tero Aittokallio5,7,
- Krister Wennerberg5,‡,
- Goutham Narla4,§ and
- Jukka Westermarck1,2,§∥
- 1Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
- 2Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
- 3TuBS and TuDMM Doctoral Programmes, University of Turku, 20520 Turku, Finland.
- 4Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106–7285, USA.
- 5Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
- 6Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- 7Department of Mathematics and Statistics, University of Turku, 20520 Turku, Finland.
- ↵∥Corresponding author. Email: jukwes{at}utu.fi
↵* Present address: Division of Functional Genomics and Systems Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE 171 77 Stockholm, Sweden.
↵† These authors contributed equally to this work.
↵‡ Present address: Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
↵§ These authors contributed equally to this work.
See allHide authors and affiliations
Science Translational Medicine 18 Jul 2018:
Vol. 10, Issue 450, eaaq1093
DOI: 10.1126/scitranslmed.aaq1093
Vol. 10, Issue 450, eaaq1093
DOI: 10.1126/scitranslmed.aaq1093
Otto Kauko
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
TuBS and TuDMM Doctoral Programmes, University of Turku, 20520 Turku, Finland.
Caitlin M. O’Connor
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106–7285, USA.
Evgeny Kulesskiy
Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
Jaya Sangodkar
Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Anna Aakula
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Sudeh Izadmehr
Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Laxman Yetukuri
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Bhagwan Yadav
Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
Artur Padzik
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Teemu Daniel Laajala
Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
Department of Mathematics and Statistics, University of Turku, 20520 Turku, Finland.
Pekka Haapaniemi
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Majid Momeny
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Taru Varila
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Michael Ohlmeyer
Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Tero Aittokallio
Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
Department of Mathematics and Statistics, University of Turku, 20520 Turku, Finland.
Krister Wennerberg
Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
Goutham Narla
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106–7285, USA.
Jukka Westermarck
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
